Ulyanovsk State University
432009, Ulyanovsk, ul. Tolstoy, 42, Ulyanovsk State University
During prospective clinical research with 90 patients suffering of Bronchial Asthma (BA) in remission stage (group I) and 90 patients suffering Chronic Obstructive Pulmonary Disease (СOPD) in remission stage (group II) have been stratified into equal subgroups IА, IБ, IВ, IIА, IIБ, IIВ according to the usage of the base inhale therapy. Patients who stopped the base therapy in the period 3-12 month before screening were included into the subgroups “A”; subgroups “B” contained the patients treated regularly with base therapy; subgroups “C” contained subjects excluded base therapy more than one year ago. During one year every three month all the patients had been tested with spirometry. It has been shown that stopping of the base therapy is a risk factor of the decreasing of the FEV1, but this risk became lower eventually.
6. Celli B.R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper / B.R. Celli, W. MacNee // Eur. Respir. J. 2004; 23: 932- 46.
7. Van Schayck S.R. Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible? / S.R.Van Schayck, P.J. van den Brock, J.J. den Otter et al. //Jama. 1995. - 274 (2): 161-164.
8. Wouter E.F.M. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial / E.F.M. Wouter, D. Postma, B. Fokkens et al. // Thorax. 2005; 60: 480-7.